Comparative healthcare resource utilization and costs of empagliflozin and <scp>GLP</scp> ‐1 receptor agonists in type 2 diabetes
Among adults with diabetes, empagliflozin was associated with similar rates of inpatient days, hospitalizations, ED, and office visits, with lower dispensed medication rates compared with GLP-1RA. Empagliflozin initiators incurred lower total costs, driven by lower glucose-lowering medication costs.
Authors
- Sebastian Schneeweiß (ORCID: https://orcid.org/0000-0003-2575-467X)
- Christina M. Shay (ORCID: https://orcid.org/0000-0002-8310-7043)
- Robert J. Glynn (ORCID: https://orcid.org/0000-0002-0697-8996)
- Arnold S. Freedman (ORCID: https://orcid.org/0000-0002-8227-8916)
- Elisabetta Patorno (ORCID: https://orcid.org/0000-0002-8809-9898)
- Niklas Schmedt (ORCID: https://orcid.org/0000-0002-6226-9537)
- Helen Tesfaye (ORCID: https://orcid.org/0000-0002-6264-2813)
- Deborah J. Wexler (ORCID: https://orcid.org/0000-0001-6979-402X)
- Julie M. Paik (ORCID: https://orcid.org/0000-0002-1315-5445)
- Phyo Than Htoo (ORCID: https://orcid.org/0000-0003-4742-8306)
- Elyse DiCesare
Institutions
- Brigham and Women's Hospital (US)
- Boehringer Ingelheim (Germany) (DE)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Boehringer Ingelheim (Egypt) (EG)
- Boehringer Ingelheim (China) (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1111/dom.70195
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00